TRIM 60-75% on any strength above $932; stop at $905; exit remainder if price breaks below $920 with volume; avoid holding through Q4 earnings as a binary catalyst

• Accounts receivable up 262% YoY signals late-cycle revenue quality deterioration, not strength
• 86% Q4 gross margin target represents peak cycle margins; normalized gross margin is 30-45%
• Forward EPS of $155 may be cut 40-70% over 18 months like prior memory cycles; halving to $77 would push P/E from 6x to 12x
• PEG of 0.14 reflects market skepticism of unrealistic peak estimates, not undervaluation
• 50 SMA declining for 2+ weeks, 10 EMA below 50 SMA, MACD histogram shrank from +12 to +1.76
• Bollinger middle band falling from $1,053 to $920.87; catching down to falling mean not base-building
• Micron didn't rally on positive SK Hynix news - textbook distribution pattern
• Net cash position ($26B cash, $6.4B debt) will fuel next cycle's capex overhang as management deploys capital
• Capex catching up to demand: Micron running $7.8B per quarter, $10.9B in construction in progress; CXMT revenue growth 874%
• Sentiment at 7.2/10 bullish - elevated and consistent with crowded trade; consensus still bullish as tape cracks
• Q4 earnings catalyst is backwards: 86% margins already priced in, soft print causes 15-20% drawdown to retest $831
• Probability-weighted downside is 40% versus 25% upside - asymmetric risk profile warrants deeper trim
• Beta of 2.21 with ATR of $60 means $895 stop will get tested and gapped in volatility events
• 200 SMA at $588 is only long-term support - not actionable until 37% drawdown from current levels

→ vs aggressive: HBM thesis provides no cycle immunity; 2017-2018 narrative (5G/cloud structural demand) and 2021-2022 narrative (data center/work from home) both ended with 50%+ drawdowns despite sounding equally compelling

→ vs aggressive: Net cash position is not protection but fuel for next cycle's supply overhang as management deploys $26B cash into capex

→ vs aggressive: Receivables up 262% YoY is late-cycle warning sign, not revenue strength; no good answer for this

→ vs aggressive: Q4 earnings as catalyst is backwards logic - already priced in, soft print causes 15-20% drawdown

→ vs aggressive: Trimming 30-50% still leaves 50-70% exposure in a 40% probability-weighted drawdown scenario with 2.21 beta

→ vs aggressive: 50 SMA rolling over is the primary technical risk actively present in the setup, contradicting neutral-to-bullish conclusion

→ vs neutral: Wait for close above $955 means chasing 2.4% rally after momentum has already re-accelerated; wait for retest of $831 means acting after 11% drawdown and crystallized losses

→ vs neutral: RSI 50.69 with no directional edge combined with declining 50 SMA, 10 EMA below that, and decelerating MACD is asymmetrically negative setup, not neutral

→ vs neutral: $873 stop at 1.5x ATR will get tested and gapped on 2.21 beta name with $60 daily ranges

→ vs neutral: Hold is inaction disguised as prudence that will lose money in this deteriorating setup

TRIM 40-50% of position on any strength above current levels targeting the 945-975 zone; retain 50-60% as a structural HBM position with stop at $895 and price target of 1000-1050 on confirmed breakout above 50 SMA; size remaining position at roughly half of normal exposure

• HBM optionality is real - CEO supply signal and NVDA $279 billion supplier commitment validate demand side, not speculative extrapolation
• Deteriorating technicals (price below declining 50 SMA, MACD decelerating, stock can't rally on good news) indicate marginal buyer exhaustion
• Conservative's 60-75% trim recommendation leaves too much money on the table for probabilistic cycle timing concerns
• Conservative's $905 stop is too tight given ATR of $60 - stop at $895 provides roughly 1.2x ATR breathing room
• Trim 40-50% (pushing toward upper end) balances cycle risk with preserving HBM structural optionality
• Target trim zone of 945-975 is conditional - execute opportunistically on any strength rather than waiting for perfect price
• Hold stance is actively choosing full downside risk in a 2.21 beta name with deteriorating technicals
• Sentiment at 7.2/10 is elevated but thesis-driven rather than momentum-driven, arguing against imminent top
• Remaining position price target 1000-1050 on confirmed breakout above 50 SMA with expanding MACD

→ vs conservative: Stop at $905 is less than half ATR from current levels - will get hit by ordinary volatility, not meaningful breakdown

→ vs conservative: Trimming 75% of position after $17.6B FCF quarter and 86% gross margin catalyst leaves enormous money on the table

→ vs conservative: Solving for multi-year cycle problem with short-term trade framework is category error

→ vs aggressive: Treating technical setup as footnote is intellectually inconsistent with being thesis-driven

→ vs aggressive: Betting against price action in beta 2.21 name with deteriorating technicals is recipe for getting run over